Johannes V. van Thienen

Author

Also Known As

Christian Blank, J Haanen, J V van Thienen, J. V. van Thienen, J. Van Thienen, J.V. Thienen, J.V. van Thienen, Johannes V. van Thienen, Johannes V van Thienen, Johannes V. Van Thienen

124

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute Melanoma Institute Australia Leiden University Medical Center The University of Sydney

About

Johannes V. van Thienen is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2.4K
2	Immunology	9	9	1.4K
3	Cell Biology	3	3	602
4	Health Sciences	2	2	86
5	Neurology	1	1	36

Johannes V. van Thienen

Publications

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma Christian U. Blank, Elisa A. Rozeman, Lorenzo F. Fanchi, Nature Medicine MedicineMelanomaImmunologyImmune Checkpoint InhibitorDermatology	2018	833
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi, The Lancet Oncology OncologyMedicineMelanomaImmune Checkpoint InhibitorDermatology	2019	498
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, New England Journal of Medicine	2022	474
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib Axel Bex, Peter F.A. Mulders, Michael A.S. Jewett, JAMA Oncology	2018	468
Endothelial KLF2 Links Local Arterial Shear Stress Levels to the Expression of Vascular Tone-Regulating Genes Rob J. Dekker, Johannes V. van Thienen, Jakub Rohlena, American Journal Of Pathology MechanobiologyEndothelial Cell PathobiologyInflammationVascular DiseaseCardiovascular Disease	2005	354
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma Jason Chesney, Antoni Ribas, Georgina V. Long, Journal of Clinical Oncology	2022	241
Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses Peter I. Bonta, Claudia M. van Tiel, Mariska Vos, Arteriosclerosis Thrombosis and Vascular Biology	2006	238
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma Yanina Jansen, Elisa A. Rozeman, Robert M. Mason, Annals of Oncology	2019	222
TDAG51 Is Induced by Homocysteine, Promotes Detachment-mediated Programmed Cell Death, and Contributes to the Development of Atherosclerosis in Hyperhomocysteinemia Gazi S. Hossain, Johannes V. van Thienen, Geoff H. Werstuck, Journal of Biological Chemistry Vascular DiseaseApoptosisImmunologyPathologyCell Death	2003	212
Primary cilia sensitize endothelial cells for fluid shear stress Beerend P. Hierck, Kim Van der Heiden, Fanneke E. Alkemade, Developmental Dynamics	2008	179

Page 1